The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.

Journal of Clinical Oncology 2026

View at publisher
Authors: Hans Gelderblom, Victoria Wang, Mark Doherty, Ana Sebio, Silvia Stacchiotti, Breelyn A. Wilky, Jean-Yves Blay, Andrew Scott Brohl, Claudia Maria Valverde Morales, Peter Reichardt, Javier Martín‐Broto, Elizabeth J. Davis
+8 more Jacco J. de Haan, Brianne O’Neill, Erin Babcock, Josep Garcia, Lane Senne, Dale Shepard, Sant P. Chawla, Robin Lewis Jones
DOI: 10.1200/jco.2026.44.16_suppl.11504
Cited by: 4

Abstract

11504 Background: Clinical outcomes for unresectable/metastatic CS are poor. There are no approved therapies, and systemic treatment options are limited. Ozekibart (INBRX-109), a novel tetravalent DR5 agonist, was evaluated in ChonDRAgon (phase 2; NCT04950075), the largest randomized, placebo (PBO)-controlled trial in advanced conventional CS. ChonDRAgon met its primary endpoint: ozekibart significantly prolonged median progression free survival (PFS) vs PBO (5.52 vs 2.66 mo; stratified HR, 0.479; 95% CI, 0.335-0.684; P

Fields of Study & Subjects

Bone Tumor Diagnosis and Treatments Cholangiocarcinoma and Gallbladder Cancer Studies Musculoskeletal synovial abnormalities and treatments

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
11504–11504
Publication date
27 May 2026
Language
EN